Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) a nasal delivery technology company has successfully undertaken a placement to institutional and sophisticated domestic and international investors at $0.21 per share. The company sought to raise a minimum of A$3.0 million and up to a maximum of A$5.0m and is pleased to report that demand saw the raise close at $A5.0 million.
Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information, go to www.rhinomed.global
Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) a leader in nasal delivery technology, today announced its 7th consecutive quarter on quarter of revenue growth. Positive trading conditions saw unaudited recognised revenues increase 30% over FY18 Q4 to $1.14m for FY19 Q1.
Rhinomed Limited (ASX:RNO) Signs 12-Year Licensing Agreement with America's Largest Medical Cannabis Operator - Columbia Care LLC
Melbourne based nasal respiratory company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.).
Rhinomed Limited (ASX:RNO) and US Based Columbia Care LLC to Develop Nasally Delivered Dose Controlled Cannabis Based Medicines
Melbourne based nasal respiratory company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC to license Rhinomed's nasal platform for the delivery of medical cannabis and cannabinoid compounds, analogues and derivatives.
Respiratory technology company Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) can report another strong quarter of growth. During the quarter the company shipped and invoiced $602k ($1.2m for the half year) worth of stock to retailers, consumers and distributors. This reflects the strength of the Company's growing global retail distribution base.
Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) a leading sleep and nasal respiratory technology company has successfully undertaken an AUD$3.6 million placement to institutional and sophisticated private investors at $0.15 per share.
Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) provides the Company's latest Investor Presentation.
The Directors of Rhinomed Limited ASX:RNO) provide the following Report in relation to the Group for the year ended 30 June 2017.
A yellow nose ring matches the yellow jersey. Chris Froome, having taken his 4th Tour de France title continues to support yellow - in the form of an innovative sports breathing device called Turbine(TM).
Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF), is pleased to announce that it has been advised that its sleep and breathing technology Mute, has been added to the annual 'large set' planogram produced by the Hamacher Resource Group, Inc.